Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
5
×
ipo
5
×
life sciences
national blog main
boston top stories
clinical trials
national top stories
san francisco blog main
san francisco top stories
sanofi
cancer drugs
fda
new york blog main
new york top stories
venture capital
biogen
boulder/denver blog main
boulder/denver top stories
deals
deerfield management
detroit blog main
detroit top stories
drug discovery
europe blog main
europe top stories
gilead sciences
indiana blog main
indiana top stories
investing
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
revolution medicines
san diego blog main
san diego top stories
san francisco
What
ipo
medicines
5
×
bio
cancer
covid
proteins
research
revolution
roundup
acquisitions
activity
announced
approvals
biogen
cancer’s
ceo
clamped
collabs
company’s
course
daniel
deal
delays
despite
developing
development
discover
disease
drug
economic
experimental
family
fast
fda
frontiers
gilead
gilead’s
growing
handiwork
hardest
Language
unset
Current search:
medicines
×
ipo
×
cancer
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline